{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:30:37Z","timestamp":1788352237384,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"crossref","award":["ZYLX201604"],"award-info":[{"award-number":["ZYLX201604"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To evaluate the clinical effectiveness of a novel CellDetect staining technique, compared with fluorescent in situ hybridization (FISH), and urine cytology, in the diagnosis of urothelial carcinoma (UC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 264 patients with suspicious UC were enrolled in this study. All tissue specimens were collected by biopsy or surgery. Urine specimen was obtained for examinations prior to the surgical procedure. CellDetect staining was carried out with CellDetect kit, and FISH was performed with UroVysion detection kit, according to the manufacturer\u2019s instructions. For urine cytology, all specimens were centrifuged using the cytospin method, and the slides were stained by standard Papanicolaou stain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In this study, there were 128 cases of UC and 136 cases of non-UC, with no significant difference in gender and age between the two groups. Results for sensitivity of CellDetect, FISH, and urine cytology were 82.8%, 83.6%, and 39.8%, respectively. The specificity of the three techniques were 88.2%, 90.4%, and 86.0%, respectively. The sensitivity of CellDetect and FISH are significantly superior compared to the conventional urine cytology; however, there was no significant difference in specificity among three staining techniques. In addition, the sensitivity of CellDetect in lower urinary tract UC, upper urinary tract UC, non-muscle-invasive bladder cancer (NMIBC), and muscle-invasive bladder cancer (MIBC) were 83.3%, 81.8%, 83.5%, and 72.0%, respectively. The screening ability of CellDetect has no correlation with tumor location and the tumor stage. The sensitivity of CellDetect in low-grade UC and high-grade UC were 51.6 and 92.8%. Thus, screening ability of CellDetect in high-grade UC is significantly superior compared to that in low-grade UC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>CellDetect and FISH show equal value in diagnosing UC, both are superior to conventional urine cytology. Compared to FISH, CellDetect is cost effective, easy to operate, with extensive clinical application value to monitor recurrence of UC, and to screen indetectable UC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12935-021-02169-3","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T11:04:58Z","timestamp":1630926298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Diagnostic value comparison of CellDetect, fluorescent in situ hybridization (FISH), and cytology in urothelial carcinoma"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6624-6834","authenticated-orcid":false,"given":"Donghao","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3932-2037","authenticated-orcid":false,"given":"Daye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"issue":"7","key":"2169_CR1","first-page":"717","volume":"80","author":"S Sharma","year":"2009","unstructured":"Sharma S, Ksheersagar P, Sharma P. Diagnosis and treatment of bladder cancer. Am Fam Physician. 2009;80(7):717\u201323.","journal-title":"Am Fam Physician"},{"issue":"2","key":"2169_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.eururo.2004.04.011","volume":"46","author":"W Oosterlinck","year":"2004","unstructured":"Oosterlinck W, Solsona E, van der Meijden AP, Sylvester R, Bohle A, Rintala E, et al. EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. Eur Urol. 2004;46(2):147\u201354.","journal-title":"Eur Urol"},{"issue":"6 Pt 1","key":"2169_CR3","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1016\/j.juro.2006.08.004","volume":"176","author":"SF Shariat","year":"2006","unstructured":"Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006;176(6 Pt 1):2414\u201322. discussion 22.","journal-title":"J Urol"},{"issue":"3","key":"2169_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/CCO.0b013e3283378c6b","volume":"22","author":"TM Morgan","year":"2010","unstructured":"Morgan TM, Clark PE. Bladder cancer. Curr Opin Oncol. 2010;22(3):242\u20139.","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"2169_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447\u201361.","journal-title":"Eur Urol"},{"issue":"2","key":"2169_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","volume":"66","author":"RS Svatek","year":"2014","unstructured":"Svatek RS, Hollenbeck BK, Holmang S, Lee R, Kim SP, Stenzl A, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014;66(2):253\u201362.","journal-title":"Eur Urol"},{"issue":"5","key":"2169_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1309\/AJCPPRZLG9KT9AXL","volume":"132","author":"F Brimo","year":"2009","unstructured":"Brimo F, Vollmer RT, Case B, Aprikian A, Kassouf W, Auger M. Accuracy of urine cytology and the significance of an atypical category. Am J Clin Pathol. 2009;132(5):785\u201393.","journal-title":"Am J Clin Pathol"},{"key":"2169_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/978-1-0716-1354-2_11","volume":"2292","author":"M Costantini","year":"2021","unstructured":"Costantini M, Gallo G, Attolini G. Urinary biomarkers in bladder cancer. Methods Mol Biol. 2021;2292:121\u201331.","journal-title":"Methods Mol Biol"},{"issue":"4","key":"2169_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.urolonc.2009.11.004","volume":"28","author":"Y Lotan","year":"2010","unstructured":"Lotan Y, Shariat SF, Schmitz-Drager BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M, et al. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol. 2010;28(4):441\u20138.","journal-title":"Urol Oncol"},{"issue":"11","key":"2169_CR10","first-page":"4761","volume":"30","author":"M Maffezzini","year":"2010","unstructured":"Maffezzini M, Campodonico F, Capponi G, Canepa G, Casazza S, Bandelloni R, et al. Prognostic significance of fluorescent in situ hybridisation in the follow-up of non-muscle-invasive bladder cancer. Anticancer Res. 2010;30(11):4761\u20135.","journal-title":"Anticancer Res"},{"key":"2169_CR11","doi-asserted-by":"publisher","first-page":"5788","DOI":"10.12659\/MSM.910134","volume":"24","author":"T Yang","year":"2018","unstructured":"Yang T, Li Y, Li J, Liu J, Deng X, Wang G. Diagnostic value comparison of urothelium carcinoma among urine exfoliated cells fluorescent in situ hybridization (FISH) examination, computerized tomography (CT) scan, and urine cytologic examination. Med Sci Monit. 2018;24:5788\u201392.","journal-title":"Med Sci Monit"},{"issue":"6","key":"2169_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/cncy.20168","volume":"119","author":"AB Galvan","year":"2011","unstructured":"Galvan AB, Salido M, Espinet B, Placer J, Pijuan L, Juanpere N, et al. A multicolor fluorescence in situ hybridization assay: a monitoring tool in the surveillance of patients with a history of non-muscle-invasive urothelial cell carcinoma: a prospective study. Cancer Cytopathol. 2011;119(6):395\u2013403.","journal-title":"Cancer Cytopathol"},{"issue":"5","key":"2169_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/cncy.20099","volume":"118","author":"NP Caraway","year":"2010","unstructured":"Caraway NP, Khanna A, Fernandez RL, Payne L, Bassett RL Jr, Zhang HZ, et al. Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study. Cancer Cytopathol. 2010;118(5):259\u201368.","journal-title":"Cancer Cytopathol"},{"issue":"12","key":"2169_CR14","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/dc.21729","volume":"40","author":"P Idelevich","year":"2012","unstructured":"Idelevich P, Kristt D, Schechter E, Lew S, Elkeles A, Terkieltaub D, et al. Screening for cervical neoplasia: a community-based trial comparing Pap staining, human papilloma virus testing, and the new bi-functional Celldetect(R) stain. Diagn Cytopathol. 2012;40(12):1054\u201361.","journal-title":"Diagn Cytopathol"},{"issue":"2","key":"2169_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ygyno.2013.12.016","volume":"132","author":"S He","year":"2014","unstructured":"He S, Wang GL, Zhu YY, Wu MH, Ji ZG, Seng J, et al. Application of the CellDetect(R) staining technique in diagnosis of human cervical cancer. Gynecol Oncol. 2014;132(2):383\u20138.","journal-title":"Gynecol Oncol"},{"key":"2169_CR16","doi-asserted-by":"crossref","unstructured":"Davis N, Shtabsky A, Lew S, Rona R, Leibovitch I, Nativ O, et al. A novel urine based assay\nfor bladder cancer diagnosis: multi institutional validation study. Eur Urol Focus. 2018;4(3):388\u201394.","DOI":"10.1016\/j.euf.2016.10.004"},{"issue":"5","key":"2169_CR17","doi-asserted-by":"publisher","first-page":"E359-86","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.","journal-title":"Int J Cancer"},{"issue":"1","key":"2169_CR18","first-page":"1","volume":"27","author":"W Chen","year":"2015","unstructured":"Chen W. Cancer statistics: updated cancer burden in China. Chin J Cancer Res. 2015;27(1):1.","journal-title":"Chin J Cancer Res"},{"issue":"4","key":"2169_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10555-015-9589-6","volume":"34","author":"M Garg","year":"2015","unstructured":"Garg M. Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer. Cancer Metastasis Rev. 2015;34(4):691\u2013701.","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"2169_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s12032-018-1152-1","volume":"35","author":"H Iwamura","year":"2018","unstructured":"Iwamura H, Hatakeyama S, Sato M, Ohyama C. Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma. Med Oncol. 2018;35(6):94.","journal-title":"Med Oncol"},{"key":"2169_CR21","first-page":"251","volume":"10","author":"M Miyake","year":"2018","unstructured":"Miyake M, Owari T, Hori S, Nakai Y, Fujimoto K. Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma. Res Rep Urol. 2018;10:251\u201361.","journal-title":"Res Rep Urol"},{"issue":"2","key":"2169_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/14737159.2019.1665509","volume":"20","author":"PS Kerr","year":"2020","unstructured":"Kerr PS, Freedland SJ, Williams SB. The current status of molecular biomarkers in patients with metastatic urothelial carcinoma of the bladder. Expert Rev Mol Diagn. 2020;20(2):127\u20139.","journal-title":"Expert Rev Mol Diagn"},{"issue":"52","key":"2169_CR23","doi-asserted-by":"publisher","first-page":"e13859","DOI":"10.1097\/MD.0000000000013859","volume":"97","author":"H Jin","year":"2018","unstructured":"Jin H, Lin T, Hao J, Qiu S, Xu H, Yu R, et al. A comprehensive comparison of fluorescence in situ hybridization and cytology for the detection of upper urinary tract urothelial carcinoma: a systematic review and meta-analysis. Medicine. 2018;97(52):e13859.","journal-title":"Medicine"},{"issue":"1","key":"2169_CR24","first-page":"8620","volume":"24","author":"LG Gomella","year":"2017","unstructured":"Gomella LG, Mann MJ, Cleary RC, Hubosky SG, Bagley DH, Thumar AB, et al. Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date. Can J Urol. 2017;24(1):8620\u20136.","journal-title":"Can J Urol"},{"issue":"1","key":"2169_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12885-017-3227-3","volume":"17","author":"HJ Lavery","year":"2017","unstructured":"Lavery HJ, Zaharieva B, McFaddin A, Heerema N, Pohar KS. A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection. BMC Cancer. 2017;17(1):247.","journal-title":"BMC Cancer"},{"issue":"8","key":"2169_CR26","first-page":"4163","volume":"11","author":"MG Balci","year":"2018","unstructured":"Balci MG, Tayfur M. Loss of E-cadherin expression in recurrent non-invasive urothelial carcinoma of the bladder. Int J Clin Exp Pathol. 2018;11(8):4163\u20138.","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"2169_CR27","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3892\/ol.2016.4671","volume":"12","author":"Y Luo","year":"2016","unstructured":"Luo Y, Zhu YT, Ma LL, Pang SY, Wei LJ, Lei CY, et al. Characteristics of bladder transitional cell carcinoma with E-cadherin and N-cadherin double-negative expression. Oncol Lett. 2016;12(1):530\u20136.","journal-title":"Oncol Lett"},{"issue":"3","key":"2169_CR28","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/MOU.0000000000000758","volume":"30","author":"JD Subiela","year":"2020","unstructured":"Subiela JD, Rodriguez Faba O, Guerrero-Ramos F, Aumatell J, Breda A, Palou J. Carcinoma in situ of the bladder: why is it underdetected? Curr Opin Urol. 2020;30(3):392\u20139.","journal-title":"Curr Opin Urol"},{"issue":"4","key":"2169_CR29","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.euf.2019.03.012","volume":"6","author":"JD Subiela","year":"2020","unstructured":"Subiela JD, Rodriguez Faba O, Guerrero Ramos F, Vila Reyes H, Pisano F, Breda A, et al. Carcinoma in situ of the urinary bladder: a systematic review of current knowledge regarding detection, treatment, and outcomes. Eur Urol Focus. 2020;6(4):674\u201382.","journal-title":"Eur Urol Focus"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02169-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-021-02169-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02169-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T11:15:41Z","timestamp":1630926941000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-021-02169-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2169"],"URL":"https:\/\/doi.org\/10.1186\/s12935-021-02169-3","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]},"assertion":[{"value":"3 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Committee of Beijing Friendship Hospital and all patients gave their informed consent before study commencement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no competing interests associated with this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"465"}}